Browsing Tag
Novavax
11 posts
Novavax offloads Maryland site to AstraZeneca for $59.8m—what does it mean for both companies?
Find out how Novavax’s Gaithersburg site transfer to AstraZeneca for $59.8M fits into its strategic refocus and what this means for future manufacturing shifts.
Sanofi taps Novavax’s Matrix-M for flu: Is NVAX stock finally turning a corner?
Novavax (NASDAQ: NVAX) expands Sanofi partnership, granting rights to Matrix-M adjuvant for pandemic flu candidates. See stock impact and outlook.
JN.1 variant: Why it still dominates global COVID-19 cases in mid-2025
JN.1 remains the most dominant COVID-19 variant in mid-2025. Explore why it still leads global cases, what WHO and CDC recommend, and how vaccines are adapting.
Fall 2025 COVID booster update: FDA endorses JN.1-based vaccine as dominant LP.8.1 strain spreads
FDA backs fall 2025 COVID booster targeting LP.8.1; rollout to begin by August. New vaccine expected to offer stronger protection against dominant variants.
Novavax shares rally after FDA approves non-mRNA COVID-19 vaccine for at-risk groups
Novavax stock surged 25% after FDA approved its non-mRNA COVID-19 vaccine Nuvaxovid. Find out what triggered this rally and what it means for investors.
Novavax’s 2024-2025 COVID-19 Vaccine Receives EUA for Use in the U.S.
Novavax, Inc. (Nasdaq: NVAX), a leading company in protein-based vaccines, has announced that its latest COVID-19 vaccine, the…
Is US facing new COVID-19 nightmare? KP.2 variant pushes hospitalization rates to record levels
The United States is grappling with the most severe COVID-19 surge since 2022, characterised by a sharp increase…
Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial
Novavax said that its Covid-19 vaccine NVX-CoV2373 achieved its primary effectiveness endpoint in the pediatric expansion of its…
Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate
Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its…
Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373,…